Contact
searchSearch
HMP Global

Ankylosing Spondylitis

Featured Article

News
Opioid Use Associated With Fractures in People With Ankylosing Spondylitis
12/20/2023
Lisa Kuhns, PhD, MD
Increasing age, historical fracture, and opioid use are associated with higher odds of fracture in ankylosing spondylitis (AS), according to a study published in Arthritis Care & Research. “We performed a retrospective cohort study...
Increasing age, historical fracture, and opioid use are associated with higher odds of fracture in ankylosing spondylitis (AS), according to a study published in Arthritis Care & Research. “We performed a retrospective cohort study...
Increasing age, historical...
12/20/2023
First Report Managed Care
News
Analysis Finds Similar Safety Profile with Upadacitinib Across Conditions
11/03/2023
Jolynn Tumolo
The Janus kinase (JAK) inhibitor upadacitinib offers a similar long-term safety profile across rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), and atopic dermatitis (AD) despite some variations in adverse...
The Janus kinase (JAK) inhibitor upadacitinib offers a similar long-term safety profile across rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), and atopic dermatitis (AD) despite some variations in adverse...
The Janus kinase (JAK) inhibitor...
11/03/2023
First Report Managed Care
News
High Rates of Depression, Anxiety in Patients With Ankylosing Spondylitis
10/06/2023
Jolynn Tumolo
Half of patients with ankylosing spondylitis had clinically significant depression, and more than a third had clinically significant anxiety, according to a single-center, cross-sectional study currently underway.
Half of patients with ankylosing spondylitis had clinically significant depression, and more than a third had clinically significant anxiety, according to a single-center, cross-sectional study currently underway.
Half of patients with ankylosing...
10/06/2023
First Report Managed Care
News
Achieving Disease Control in PsA, AS Associated with Lower Medical Costs
09/15/2023
Jolynn Tumolo
A study published in Rheumatology and Therapy found that individuals diagnosed with psoriatic arthritis (PsA) or ankylosing spondylitis (AS) and exhibiting lower levels of disease activity incurred reduced healthcare resource utilization and...
A study published in Rheumatology and Therapy found that individuals diagnosed with psoriatic arthritis (PsA) or ankylosing spondylitis (AS) and exhibiting lower levels of disease activity incurred reduced healthcare resource utilization and...
A study published in...
09/15/2023
First Report Managed Care
News
Can Tumor Necrosis Factor Inhibitors Reduce the Risk of Fractures in AS Patients?
08/30/2023
Danielle Sposato
Researchers sought to understand if fracture risk decreased among individuals with ankylosing spondylitis with tumor necrosis factor inhibitors treatments compared to non-AS patients.
Researchers sought to understand if fracture risk decreased among individuals with ankylosing spondylitis with tumor necrosis factor inhibitors treatments compared to non-AS patients.
Researchers sought to understand...
08/30/2023
First Report Managed Care
News
Fear of Movement in Patients With Ankylosing Spondylitis Linked With Lower Life Quality
07/27/2023
Jolynn Tumolo
Research findings indicate a link between kinesiophobia, a fear of movement and injury, and decreased quality of life in patients with ankylosing spondylitis.
Research findings indicate a link between kinesiophobia, a fear of movement and injury, and decreased quality of life in patients with ankylosing spondylitis.
Research findings indicate a...
07/27/2023
First Report Managed Care
News
Tildrakizumab No Better Than Placebo for Ankylosing Spondylitis
06/09/2023
Jolynn Tumolo
A 48-week trial of tildrakizumab in patients with ankylosing spondylitis was terminated early after researchers found that the drug had no efficacy in comparison to placebo.
A 48-week trial of tildrakizumab in patients with ankylosing spondylitis was terminated early after researchers found that the drug had no efficacy in comparison to placebo.
A 48-week trial of tildrakizumab...
06/09/2023
First Report Managed Care
News
Risk of Psychiatric Comorbidity Higher in Patients With Ankylosing Spondylitis
05/19/2023
Jolynn Tumolo
Findings from a population-based, cross-sectional study suggest that patients with ankylosing spondylitis are at a higher risk of developing psychiatric disorders.
Findings from a population-based, cross-sectional study suggest that patients with ankylosing spondylitis are at a higher risk of developing psychiatric disorders.
Findings from a...
05/19/2023
First Report Managed Care
News
Short-term Biosimilar Adalimumab Provides Long-term Relief for Ankylosing Spondylitis
04/14/2023
Jolynn Tumolo
Treatment with biosimilar adalimumab was associated with a significant improvement in ankylosing spondylitis symptoms for up to 1 year, according to new findings.
Treatment with biosimilar adalimumab was associated with a significant improvement in ankylosing spondylitis symptoms for up to 1 year, according to new findings.
Treatment with biosimilar...
04/14/2023
First Report Managed Care
News
JAK Inhibitor Improves Slate of Patient-Reported Outcomes in Biologic Refractory Ankylosing Spondylitis
03/28/2023
Jolynn Tumolo
Researchers studied a JAK inhibitor's efficacy for improving disease activity, health-related quality of life, and other measures in a cohort of patients with ankylosing spondylitis who did not respond or tolerate biologics.
Researchers studied a JAK inhibitor's efficacy for improving disease activity, health-related quality of life, and other measures in a cohort of patients with ankylosing spondylitis who did not respond or tolerate biologics.
Researchers studied a JAK...
03/28/2023
First Report Managed Care
News
Baseline Variables Predict Probability of Initial Response to TNFi Inhibitors in Patients With AS
10/27/2022
Edan Stanley
Researchers sought to develop models of the probability of short-term response to tumor necrosis factor inhibitor treatment in patients with ankylosing spondylitis.
Researchers sought to develop models of the probability of short-term response to tumor necrosis factor inhibitor treatment in patients with ankylosing spondylitis.
Researchers sought to develop...
10/27/2022
First Report Managed Care

Newsfeed

News
Opioid Use Associated With Fractures in People With Ankylosing Spondylitis
12/20/2023
Lisa Kuhns, PhD, MD
Increasing age, historical fracture, and opioid use are associated with higher odds of fracture in ankylosing spondylitis (AS), according to a study published in Arthritis Care & Research. “We performed a retrospective cohort study...
Increasing age, historical fracture, and opioid use are associated with higher odds of fracture in ankylosing spondylitis (AS), according to a study published in Arthritis Care & Research. “We performed a retrospective cohort study...
Increasing age, historical...
12/20/2023
First Report Managed Care
News
Analysis Finds Similar Safety Profile with Upadacitinib Across Conditions
11/03/2023
Jolynn Tumolo
The Janus kinase (JAK) inhibitor upadacitinib offers a similar long-term safety profile across rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), and atopic dermatitis (AD) despite some variations in adverse...
The Janus kinase (JAK) inhibitor upadacitinib offers a similar long-term safety profile across rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), and atopic dermatitis (AD) despite some variations in adverse...
The Janus kinase (JAK) inhibitor...
11/03/2023
First Report Managed Care
News
High Rates of Depression, Anxiety in Patients With Ankylosing Spondylitis
10/06/2023
Jolynn Tumolo
Half of patients with ankylosing spondylitis had clinically significant depression, and more than a third had clinically significant anxiety, according to a single-center, cross-sectional study currently underway.
Half of patients with ankylosing spondylitis had clinically significant depression, and more than a third had clinically significant anxiety, according to a single-center, cross-sectional study currently underway.
Half of patients with ankylosing...
10/06/2023
First Report Managed Care
News
Achieving Disease Control in PsA, AS Associated with Lower Medical Costs
09/15/2023
Jolynn Tumolo
A study published in Rheumatology and Therapy found that individuals diagnosed with psoriatic arthritis (PsA) or ankylosing spondylitis (AS) and exhibiting lower levels of disease activity incurred reduced healthcare resource utilization and...
A study published in Rheumatology and Therapy found that individuals diagnosed with psoriatic arthritis (PsA) or ankylosing spondylitis (AS) and exhibiting lower levels of disease activity incurred reduced healthcare resource utilization and...
A study published in...
09/15/2023
First Report Managed Care
News
Can Tumor Necrosis Factor Inhibitors Reduce the Risk of Fractures in AS Patients?
08/30/2023
Danielle Sposato
Researchers sought to understand if fracture risk decreased among individuals with ankylosing spondylitis with tumor necrosis factor inhibitors treatments compared to non-AS patients.
Researchers sought to understand if fracture risk decreased among individuals with ankylosing spondylitis with tumor necrosis factor inhibitors treatments compared to non-AS patients.
Researchers sought to understand...
08/30/2023
First Report Managed Care
News
Fear of Movement in Patients With Ankylosing Spondylitis Linked With Lower Life Quality
07/27/2023
Jolynn Tumolo
Research findings indicate a link between kinesiophobia, a fear of movement and injury, and decreased quality of life in patients with ankylosing spondylitis.
Research findings indicate a link between kinesiophobia, a fear of movement and injury, and decreased quality of life in patients with ankylosing spondylitis.
Research findings indicate a...
07/27/2023
First Report Managed Care
News
Tildrakizumab No Better Than Placebo for Ankylosing Spondylitis
06/09/2023
Jolynn Tumolo
A 48-week trial of tildrakizumab in patients with ankylosing spondylitis was terminated early after researchers found that the drug had no efficacy in comparison to placebo.
A 48-week trial of tildrakizumab in patients with ankylosing spondylitis was terminated early after researchers found that the drug had no efficacy in comparison to placebo.
A 48-week trial of tildrakizumab...
06/09/2023
First Report Managed Care
News
Risk of Psychiatric Comorbidity Higher in Patients With Ankylosing Spondylitis
05/19/2023
Jolynn Tumolo
Findings from a population-based, cross-sectional study suggest that patients with ankylosing spondylitis are at a higher risk of developing psychiatric disorders.
Findings from a population-based, cross-sectional study suggest that patients with ankylosing spondylitis are at a higher risk of developing psychiatric disorders.
Findings from a...
05/19/2023
First Report Managed Care
News
Short-term Biosimilar Adalimumab Provides Long-term Relief for Ankylosing Spondylitis
04/14/2023
Jolynn Tumolo
Treatment with biosimilar adalimumab was associated with a significant improvement in ankylosing spondylitis symptoms for up to 1 year, according to new findings.
Treatment with biosimilar adalimumab was associated with a significant improvement in ankylosing spondylitis symptoms for up to 1 year, according to new findings.
Treatment with biosimilar...
04/14/2023
First Report Managed Care
News
JAK Inhibitor Improves Slate of Patient-Reported Outcomes in Biologic Refractory Ankylosing Spondylitis
03/28/2023
Jolynn Tumolo
Researchers studied a JAK inhibitor's efficacy for improving disease activity, health-related quality of life, and other measures in a cohort of patients with ankylosing spondylitis who did not respond or tolerate biologics.
Researchers studied a JAK inhibitor's efficacy for improving disease activity, health-related quality of life, and other measures in a cohort of patients with ankylosing spondylitis who did not respond or tolerate biologics.
Researchers studied a JAK...
03/28/2023
First Report Managed Care
Behind the Bill
New Bill Would Expand Medicare and Medicaid Access to Community Health Workers
09/18/2026
Hannah Musick
The Community Health Worker Access Act would expand Medicare reimbursement for community health worker services and incentivize states to broaden Medicaid coverage, potentially strengthening care navigation, preventive support, and...
The Community Health Worker Access Act would expand Medicare reimbursement for community health worker services and incentivize states to broaden Medicaid coverage, potentially strengthening care navigation, preventive support, and...
The Community Health Worker...
09/18/2026
First Report Managed Care
News
US Vitiligo Study Finds Short Treatment Duration, Variable Care Patterns
09/18/2026
Grace Taylor, MS, MA
A study found that US patients with vitiligo showed short treatment durations and highly variable treatment patterns, while approximately one-third received no treatment following diagnosis.
A study found that US patients with vitiligo showed short treatment durations and highly variable treatment patterns, while approximately one-third received no treatment following diagnosis.
A study found that US patients...
09/18/2026
First Report Managed Care
News
GLP-1 Coverage Linked to Higher Utilization and Costs in Employer-Sponsored Health Plans
09/17/2026
Rebecca Amrick
Researchers found that between 2021 and 2024, utilization of glucagon-like peptide-1 (GLP-1) medications increased among patients with obesity, with greater growth among plans providing coverage for GLP-1 drugs.
Researchers found that between 2021 and 2024, utilization of glucagon-like peptide-1 (GLP-1) medications increased among patients with obesity, with greater growth among plans providing coverage for GLP-1 drugs.
Researchers found that between...
09/17/2026
First Report Managed Care
News
Epcoritamab Plus R2 Demonstrates Long-Term Cost-Effectiveness in Relapsed or Refractory FL
09/17/2026
Rebecca Amrick
A cost-effectiveness analysis indicated that adding epcoritamab to lenalidomide plus rituximab (R2) could reduce long-term health care spending for patients with relapsed or refractory follicular lymphoma (FL).
A cost-effectiveness analysis indicated that adding epcoritamab to lenalidomide plus rituximab (R2) could reduce long-term health care spending for patients with relapsed or refractory follicular lymphoma (FL).
A cost-effectiveness analysis...
09/17/2026
First Report Managed Care
News
Fewer PA Requirements Among System-Affiliated MA Health Plans
09/16/2026
Rebecca Amrick
Medicare Advantage (MA) plans affiliated with health systems had fewer prior authorization (PA) requirements than unaffiliated plans, with the largest differences observed for behavioral and mental health services and dialysis.
Medicare Advantage (MA) plans affiliated with health systems had fewer prior authorization (PA) requirements than unaffiliated plans, with the largest differences observed for behavioral and mental health services and dialysis.
Medicare Advantage (MA) plans...
09/16/2026
First Report Managed Care
News
Monitoring Ruxolitinib Responses Could Optimize Treatment for Polycythemia Vera
09/16/2026
Rebecca Amrick
Monitoring spleen and hematologic responses in patients with ruxolitinib-treated polycythemia vera (PV) enabled researchers to develop a prognostic model that may help physicians identify patients at increased risk of poor outcomes.
Monitoring spleen and hematologic responses in patients with ruxolitinib-treated polycythemia vera (PV) enabled researchers to develop a prognostic model that may help physicians identify patients at increased risk of poor outcomes.
Monitoring spleen and...
09/16/2026
First Report Managed Care
News
The Impact of Atopic Comorbidities on Health Care Utilization for Atopic Dermatitis
09/15/2026
Rebecca Amrick
New research suggests an association between atopic comorbidities and health care utilization and costs among young children with atopic dermatitis.
New research suggests an association between atopic comorbidities and health care utilization and costs among young children with atopic dermatitis.
New research suggests an...
09/15/2026
First Report Managed Care
News
Real-World Study Identifies Factors Associated With Successful TKI Discontinuation in CML
09/14/2026
Rebecca Amrick
Among patients with CML who discontinued TKI therapy, sustained deep molecular response, lower Sokal scores, and longer treatment duration were associated with a greater likelihood of maintaining treatment-free remission.
Among patients with CML who discontinued TKI therapy, sustained deep molecular response, lower Sokal scores, and longer treatment duration were associated with a greater likelihood of maintaining treatment-free remission.
Among patients with CML who...
09/14/2026
First Report Managed Care
Behind the Bill
House Panel Weighs Medicare Payment Reform and Health Care Cybersecurity Legislation
09/14/2026
Hannah Musick
A House panel is weighing bipartisan proposals that could reshape Medicare physician payments and strengthen health care cybersecurity, with potential implications for provider reimbursement, value-based care, network stability, and cyber...
A House panel is weighing bipartisan proposals that could reshape Medicare physician payments and strengthen health care cybersecurity, with potential implications for provider reimbursement, value-based care, network stability, and cyber...
A House panel is weighing...
09/14/2026
First Report Managed Care
News
The Cost-Effectiveness of the JAKPOT Prediction Rule for Erythrocytosis
09/11/2026
Rebecca Amrick
Researchers found upfront JAK2 testing to be more cost-effective in US settings than the JAKPOT predication rule when identifying JAK2 mutations among patients with erythrocytosis.
Researchers found upfront JAK2 testing to be more cost-effective in US settings than the JAKPOT predication rule when identifying JAK2 mutations among patients with erythrocytosis.
Researchers found upfront JAK2...
09/11/2026
First Report Managed Care

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use